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Purpose: Despite the role of carbon monoxide in ameliorating ischemia-reperfusion injury (IRI), its use in the clinical setting is re-
stricted owing to its toxicity. Herein, we investigated the in vivo effects of carbon monoxide–releasing molecule-3 (CORM-3) on IRI.
Materials and Methods: Fifteen rats were equally and randomly divided into three groups: sham (right nephrectomy), control 
(right nephrectomy and left renal ischemia), and CORM-3 (right nephrectomy and CORM-3 injection before left renal ischemia). 
Kidney tissues and blood samples collected from sacrificed rats were evaluated to determine the renoprotective effect and mecha-
nism of CORM-3.
Results: Concentrations of serum creatinine and kidney injury molecule-1 in the CORM-3 group were significantly lower than in 
the control group after 75 minutes of IRI (1.2 vs. 2.4 mg/dL, p=0.01, and 292 vs. 550 pg/mL, p<0.001, respectively). Furthermore, 
the CORM-3 group exhibited a higher portion of normal tubules and glomeruli. TUNEL staining revealed fewer apoptotic renal tu-
bular cells in the CORM-3 group than in the control group. The expression of 960 genes in the CORM-3 group was also altered. Pre-
treatment with CORM-3 before renal IRI produced a significant renoprotective effect. Fifteen of the altered genes were found to be 
involved in the peroxisome proliferator-activated receptors signaling pathway, and the difference in the expression of these genes 
between the CORM-3 and control groups was statistically significant (p<0.001).
Conclusions: CORM-3 ameliorates IRI by decreasing apoptosis and may be a novel strategy for protection against renal warm IRI.
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INTRODUCTION
Ischemia-reperfusion injury (IRI) reduces intracellular 
levels of ATP and causes ion channel damage leading to 
cell death [1]. The cells of the renal cortex are vulnerable to 
changes in oxygen concentration and IRI. The temporary 
clamping of the renal artery and vein before renal mass 
excision and renorrhaphy during partial nephrectomy to su-
ture the excised renal tissue can also cause IRI. To prevent 




rounded by ice-cold saline packs at the start of the procedure 
(cold ischemia) [2]. However, recent advances in minimally 
invasive surgical techniques have made it difficult and time 
consuming to place ice inside the abdominal cavity during 
laparoscopic or robotic partial nephrectomy. Warm IRI can 
be prevented or minimized if the ischemia time is less than 
25 minutes [3]. However, a recent study showed that, despite 
limiting the ischemia time to less than 20 minutes, the risk 
of renal injury increases by 6% for every 1-minute increase 
in ischemia time [4]. Even a single instance of acute renal 
injury can increase the risk for chronic renal failure by 40%. 
The frequency of partial nephrectomy has increased geomet-
rically in recent years and currently accounts for over 70% 
of all renal tumor surgeries. In addition, as life expectancy 
has increased, the importance of preserving renal function 
after the surgical removal of renal tumors has increased. 
Indeed, a recent analysis of surgical outcomes for kidney 
cancer evaluated the importance of functional outcomes [5].
In addition to partial nephrectomy, IRI can occur dur-
ing renal transplantation. The donor kidney is in a state of 
ischemia until anastomosis with the recipient blood vessels, 
and injury can occur during reperfusion after anastomosis. 
Moreover, methods more effective than low-temperature ice 
storage of the donor kidney during transit have not yet been 
developed [6]. The role of carbon monoxide (CO) in renal IRI 
has been a subject of interest since the 2000s [7]. However, 
there has been limited animal study of the role of CO in 
IRI in the kidney. One study demonstrated that inhalation 
of low-dose CO together with anaesthetic gas can improve 
renal function in porcine kidney transplantation recipients. 
The authors suggested inflammatory modulation as a mech-
anism for the effects of CO [8]. Another study demonstrated 
that the oxygen-binding capacity of CO is approximately 40-
fold that of hemoglobin, identifying CO as a molecule that 
can deliver oxygen to ischemic organs [7]. Therefore, atten-
tion has turned to CO-releasing molecule (CORM). A CORM 
compound was first developed to deliver CO to biological 
target organs by researchers in the United Kingdom (UK) 
[9,10]. There are several subtypes of CORM; however, CORM-
3 shows excellent water solubility and rapidly releases CO 
in physiologic fluids [10]. Therefore, in this study, we aimed 
to investigate the effects of CORM-3 on IRI of the kidney, 
prove its mechanism of action, and explore its potential for 
clinical application.
MATERIALS AND METHODS
1. Animals and experimental design
The study was approved by the Institutional Animal 
Care and Use Committee, Hanyang University College of 
Medicine, in accordance with the Guide for the Care and Use 
of Laboratory Animals published by the National Institutes 
of Health and was performed in accordance with approved 
guidelines (no. 2018-0053A).
We created a renal IRI model using 8-week-old male 
Sprague–Dawley rats (SD rats; OrientBio, Seongnam, Korea). 
Rats were divided into three groups. Animals in the sham 
group (n=5/group) underwent right nephrectomy; ischemia 
was not induced, and the abdominal cavity was opened for 
the usual duration of ischemia and then sutured and closed. 
Animals in the IRI group (n=5/group) underwent right ne-
phrectomy, and a bulldog clamp was used to occlude the left 
renal artery and vein. Animals in the CORM-3 group (n=5/
group) were injected with CORM-3 (10 mg/kg) in the tail 
vein 1 hour preoperatively and were then subjected to the 
same procedure as those in the IRI group.
The detailed surgical procedures are presented in Supple-
mentary material. 
2. TUNEL assay
Renal tissue that had been stored and fixed in 4% form-
aldehyde was treated with ethanol and xylene, and paraffin-
embedded samples were cut into 4-µm-thick sections and 
prepared as slides. After using xylene to remove the paraf-
fin, the tissue was rehydrated using 100%, 90%, 80%, and 
70% ethanol. The renal tissue was then soaked in Protein-
ase K solution (20 µg/mL) prepared in 10 mM Tris/HCl (pH 
7.4–8), incubated for 15 minutes at room temperature (25ºC 
to 27ºC), and washed with phosphate-buffered saline (PBS). 
We used the In Situ Cell Death Detection Kit, Fluorescein 
(Roche, Basel, Switzerland) to prepare a mixture of the en-
zyme solution (5 µL) and label solution (45 µL). The prepared 
mixture (50 µL) was dripped onto the renal tissue, which 
was then covered with a cover slip. The slides were left to 
react at 37ºC for 1 hour and were washed with PBS after 
the completion of the reaction. Finally, the kidney tissue was 
soaked in a 1 μg/mL Hoechst 33342 (2'-[4-ethoxyphenyl]-5-[4-
methyl-1-piperazinyl]-2,5'-bi-1H-benzimidazole trihydrochloride 
trihydrate; Thermo Scientific, Waltham, MA, USA) solution 
prepared in PBS and left to react for 15 minutes at room 
temperature. The tissue was washed with PBS and mounted 
using VECTASHIELD Antifade Mounting Medium (Vec-
tor Laboratories, Burlingame, CA, USA). Areas of cell death 
were identified as green fluorescence in the cellular nuclei 
(stained in blue) under a light microscope (Leica Microsys-
tems, Wetzar, Germany).
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3. Picro-sirius red staining
Xylene was used to remove paraffin from 4-µm-thick re-
nal tissue slides, and the tissue was rehydrated in 100%, 90%, 
80%, and 70% ethanol and washed with distilled water (DW). 
The tissue was stained with Picro-sirius red solution (Abcam, 
Cambridge, UK) for 1 hour at room temperature. Thereafter, 
it was washed twice in 0.5% acetic acid solution; hydrated in 
70%, 80%, 90%, and 100% ethanol; treated with xylene; and 
mounted using Consul-Mount Histology Formulation (Ther-
mo Scientific). 
4. Immunohistochemical staining
Xylene was used to remove paraffin from 4-µm-thick re-
nal tissue slides, and the tissue was rehydrated in 100%, 90%, 
80%, and 70% ethanol and washed with DW. The slides were 
treated with sodium citrate buffer (pH 6.0), placed in a micro-
wave, and heated for 15 minutes for antigen retrieval. After 
dripping 0.3% Triton X-100/PBS onto the kidney tissue, the 
tissue was left to react for 10 minutes at room temperature 
and washed with PBS. For blocking, the kidney tissue was 
treated with 10% normal donkey serum (Abcam, Cambridge, 
MA, USA), diluted in PBS, for 1 hour at room temperature. 
After blocking, the tissue was treated with the primary an-
tibody (KIM-1; R&D Systems, Minneapolis, MN, USA) diluted 
in PBS. After completion of the antibody reaction, the tissue 
was washed in PBS and diaminobenzidine (DAB) staining 
was performed. The renal tissue was reacted with the DAB 
mixture (DAB stock, 100 µL; Buffer stock, 84 µL; hydrogen 
peroxide, 80 µL; and DW) prepared by following the manual 
of the DAB Substrate Kit (Vector Laboratories). Thereafter, 
the tissue was washed in DW and briefly immersed in hema-
toxylin staining solution 20 times for nuclear staining. The 
tissue was hydrated using 70%, 80%, 90%, and 100% ethanol 
and mounted using the Consul-Mount Histology Formulation 
(Thermo Scientific).
5. cDNA microarray
For each sample, 100 ng of RNA was amplified and la-
beled with Cy3-dCTP. The labeled cRNAs were purified us-
ing the RNAeasy Mini Kit (Qiagen, Hilden, Germany), and 
the concentration of labeled cRNAs (pmol Cy3/μg cRNA) 
was measured using an ND-1000 Spectrophotometer. cRNAs 
(600 ng) were added to 5 µL of 10× blocking agent and 1 µL 
of 25× fragmentation buffer, and the mixture was heated 
for 30 minutes at 60ºC. Finally, cRNAs were diluted in 25 µL 
of 2× GE hybridization buffer. After 40 µL of hybridization 
solution was transferred to gasket slides, the slides were as-
sembled into Agilent SurePrint G3 Human GE 8X60K, V3 
Microarrays (Agilent, Santa Clara, CA, USA). Raw data were 
obtained using Agilent Feature Extraction Software (v11.0.1.1) 
and summarized in the Agilent feature extraction protocol 
to produce a raw data text file. The Flag A-tagged array 
probes were filtered. The selected gProcessed signal value 
was subjected to logarithmic transformation and normalized 
using the quantile method. The statistical significance of the 
expression data was determined by the fold change between 
the two groups and was verified by an independent t-test. 
Hierarchical cluster analysis was performed using complete 
linkage and Euclidean distance as measures of similarity. 
Gene Ontology (http://geneontology.org) and KEGG (http://
kegg.jp) were used to perform gene-enrichment and func-
tional annotation analysis of the probe list. Data analyses 
and visualization of genes showing significant differences 
were performed using R3.0.2 (www.r-project.org).
RESULTS
1. Changes in blood creatinine levels
Blood creatinine levels were measured to assess in vivo 
renal function (Fig. 1). The sham group showed no signifi-
cant changes in blood creatinine levels; however, the IRI 
group showed a gradual increase in the blood creatinine 
level in the 60-minute ischemia model and a large increase 
in the 75-minute ischemia model. The CORM-3 group showed 
lower blood creatinine levels after 75 minutes of ischemia 
than in the IRI group, which was not administered CORM-3 
(1.2 vs. 2.4 mg/dL, p=0.01). The 75-minute ischemia model was 
selected for further experiments because it showed the larg-























Fig. 1. Serum creatinine concentrations at 1 day after ischemia-reper-
fusion injury (IRI). In the 30-minute and 45-minute IRI experiments, 
there were no significant differences among the groups, but the effect 
of carbon monoxide–releasing molecule-3 (CORM-3) was seen in IRI 




2. Changes in the level of renal injury markers
We measured blood levels of the renal injury markers 
KIM-1, cystatin-C, and beta 2-microglobulin. Blood concen-
trations of all three markers were higher in the IRI group 
than in the sham group. KIM-1 and cystatin-C levels were 
significantly lower in the CORM-3 group than in the IRI 
group (550.4±55.9 vs. 292±68.6 pg/mL, p<0.001, and 3,933.7±106.1 
vs. 3,324.9±309.8 ng/mL, p=0.01, respectively). Furthermore, 
the level of beta 2-microglobulin was lower in the CORM-
3 group than in the IRI group (p=0.116, Fig. 2), although the 
difference was not statistically significant.
3.  Histologic tests (hematoxylin and eosin staining, 
TUNEL assay, and immunohistochemical assay)
We used histologic tests in experimental animals to de-
termine changes in tissue morphology caused by IRI and 
CORM-3. Hematoxylin and eosin staining revealed normal 
tubule appearance of the kidney tissue in the sham group 
(Fig. 3). However, the IRI group exhibited severe tubular dil-
atation (open lumen) and tubular epithelial thinning. More-
over, extensive accumulation of intraluminal cytoplasmic 
debris and necrosis of the tubular epithelium were observed 
at both high (×400) and low (×100) magnification. Conversely, 
the CORM-3 group showed only partial tubular thinning, 
and no necrosis was observed.
The TUNEL assay was performed to determine apoptotic 
activity in the kidney. The sham group exhibited few apop-
totic cells; however, the level of apoptosis increased mark-
edly in the IRI group, and CORM-3 administration reduced 
the number of apoptotic cells (Fig. 4). Immunohistochemistry 
was performed to determine the levels of KIM-1 in the renal 
tissue. As expected, the CORM-3 group showed lower KIM-
1 levels than in the IRI group (p=0.003, Fig. 5). Furthermore, 
we used Picro-sirius red staining to examine the extent of 
fibrosis in the renal tissue. The CORM-3 group showed less 
fibrosis than in the IRI group; however, the difference was 
not statistically significant (p=0.115, Fig. 6).
4. cDNA microarray
Of the 45,598 probes detected by cDNA microarray anal-
ysis, 3,820 showed significant differences. In the IRI group, 
3,746 genes showed altered expression, while the expression 
of  only 960 genes was altered in the CORM-3 group. As 
shown in the Venn diagram plots (Fig. 7), the genes with ab-
errant expression in the CORM-3 group were mostly concor-
dant with those in the IRI group. We observed 1,379 and 1,481 
genes that were upregulated and downregulated, respec-














































































Fig. 2. (A–C) In vivo model of renal injury markers. *p<0.05 compared 
with ischemia-reperfusion injury (IRI) group. CORM-3, carbon monox-
ide–releasing molecule-3.
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prevents changes in gene expression associated with IRI.
We also studied the pathways involving genes with abe-
rrant expression in the IRI group and identified five path-
ways, including the metabolic and PI3K-Akt signaling path-
ways (Table 1). In the CORM-3 group, the expression of these 
genes was poor or not detected.
Differences in the expression of genes associated with 
the peroxisome proliferator-activated receptors (PPAR) sig-
naling pathway, glycolysis, gluconeogenesis, amino acid bio-
synthesis, vascular smooth muscle contraction or relaxation, 
steroid hormone biosynthesis, and fatty acid metabolism 
were observed between the IRI and CORM-3 groups. A total 
of 15 genes were found to be involved in the PPAR signaling 
pathway (MCAD, LXR-alpha, SLC27A2, EHHADH, ACSL1, 
Perilipin-2, PPAR-alpha, CYP4A1, CYP4A2, CYP4A3, CY-
P4A8, HMGCS2, PEPCK1, RXR-gamma, and glycerol kinase), 
and the difference in the expression of these genes was sta-
tistically significant (p<0.001, Fig. 8). 
In order to analyze changes in the expression of genes 
involved in the PPAR signaling pathway in the sham, IRI, 
and CORM-3 groups, gene-specific primers were designed 
and reverse transcription polymerase chain reaction was 
performed. The expression of  PPAR pathway genes was 
significantly lower in the IRI group than in the sham group. 
Moreover, the expression of PPAR pathway genes was hi-
gher in the CORM-3 group than in the IRI group (Fig. 9). 
These results suggest that pretreatment with CORM-3 may 
inhibit IRI by upregulating genes associated with the PPAR 
signaling pathway.
DISCUSSION
The aim of this study was to demonstrate by use of a rat 
model the ability of CORM-3 to prevent and treat renal IRI. 
We showed that CORM-3 pretreatment can reduce cell death 





Fig. 3. Hematoxylin and eosin staining of 
kidney. (A) Sham, (B) ischemia-reperfusion 





growth. The results of the immunohistochemistry, pathologic 
examination, and cDNA microarray analyses show ed that 
CORM-3 pretreatment can preserve renal function. CORM-3 
reduces renal IRI through the upregulation of genes involved 
in the PPAR signaling pathway.
Several previous studies investigated mechanisms to 
prevent or minimize renal IRI. One study developed a model 
to minimize IRI by using ischemic preconditioning with 
bradykinins, antioxidants, and inflammatory molecules. In 
that study, Yoon et al. [11] conducted an in vivo study of 
remote ischemic preconditioning to determine its underly-
ing mechanism. When applied in a clinical setting to partial 
nephrectomy for patients with a renal mass, because of the 
difficulties in actually performing two rounds of anesthesia 
and surgery, chemical treatment methods for renal IRI have 
been suggested. Studies conducted in the 2010s involved 
pretreatment with sildenafil, udenafil, or L-arginine and 
α-tocopherol to treat IRI [12-14]. These methods were reported 
to alleviate IRI by increasing renal blood flow and reducing 
neutrophil activity, reactive oxygen species levels, and plate-
let aggregation. Subsequent studies used hydrogen sulfide to 
treat IRI in renal transplantation patients. The vasodilatory 
effect of hydrogen sulfide on microvascular flow was en-
hanced by concomitant administration of CO. However, the 
role of hydrogen sulfide in inflammatory modulation is still 
debated; hydrogen sulfide has also been shown to aggravate 
sepsis owing to neutrophil migration [15,16].
Interestingly, CO has been reported to play a protec-
tive role in a rodent kidney warm IRI model [17,18]. CO was 
initially used for inhalation therapy. CO gas is relatively 
nonreactive and is simple to administer, with well-described 
pharmacodynamics. Low-dose CO inhalation therapy has 
been used in clinical practice in pulmonary and vascular 
diseases such as pulmonary fibrosis, ventilator-induced lung 
injury, and diabetes. CORM, unlike CO gas inhalation, has 





Fig. 4. TUNEL assay of kidney. (A) Sham, (B) ischemia-reperfusion injury group, and (C) carbon monoxide–releasing molecule-3 group.
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specific delivery and through a range of CO release kinetics. 
Additionally, CORM can be used to deliver small amounts 
of CO to biological systems in a controlled manner and could 
deliver CO to tissues with less COHb compared with inhaled 
CO [10,19]. Recent research has demonstrated that metal car-

























Fig. 5. (A, B) Immunohistochemistry of kidney injury molecule-1 
(×400). *p=0.003 compared with ischemia-reperfusion injury (IRI) 
















Fig. 6. (A, B) Sirius red staining of kidney (×400). IRI, ischemia-reperfu-




1 and CORM-2 are hydrophobic. In this study, CORM-3 
[Ru(CO)3Cl(glycinato)] was used, which has excellent water 
solubility at pH 3 and rapidly releases CO in physiologic flu-
ids. CORM-3 was administered intravenously 1 hour before 
IRI. No studies have yet been conducted to determine the 
most effective time of CORM-3 administration before isch-
emia. Further research will be required to investigate the 
optimal time of administration of CORM-3.
There have been several efforts in the urology field to 
elucidate the genes related to the IRI pathway [21]. Toll-like 
receptors, sphingosine-1-phosphate receptors, and hypoxia-
inducible factors have been reported to worsen tubular 
epithelial cell function, eventually causing acute renal dam-
age, delayed graft function, and ultimately acute-on-chronic 
rejection [22]. In this study, metabolic pathways, the PI3K-
Akt signaling pathway, oxidative phosphorylation, carbon 
metabolism, and the cell cycle were found to be involved in 




























MMP1 PDK-1 PEPCK GYK
Fig. 8. Genes in the peroxisome proliferator-activated receptors (PPAR) signaling pathway with altered expression in the carbon monoxide–releasing 
molecule-3 group compared with the ischemia-reperfusion injury group. VLDL, very low density lipoprotein; FATP, fatty acid transport proteins; FAT/CD36, 
fatty acid translocase/CD36; FABP, fatty acid binding protein; RXR, retinoid X receptor; ACS, acyl-CoA synthetase; Bien, bifunctional enzyme; MMP1, matrix 
metalloproteinase-1; PDK-1, pyruvate dehydrogenase kinase 1; PEPCK, phosphoenolpyruvate carboxykinase; GYK, glycerol kinase; Apo-AI, apolipopro-
tein A-I; CYP4A1, cytochrome P450, family 4, subfamily a.




Fig. 7. Venn diagrams of altered gene expression. (A) Upregulated 
by two-fold or more, (B) downregulated by two-fold or more. IRI, 
ischemia-reperfusion injury; CORM-3, carbon monoxide–releasing 
molecule-3.
Table 1. Genes of the KEGG pathway with altered expression in the 





Metabolic pathways 346 93
PI3K-Akt signaling pathway 70 21
Oxidative phosphorylation 53 N/A
Carbon metabolism 50 17
Cell cycle 39 25
N/A, not applicable.
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showed altered expression. We hypothesize that CORM-3 
prevents changes in gene expression by protecting against 
renal IRI. Indeed, the CORM-3 group showed significantly 
less gene expression than the IRI group.
The PPAR signaling pathway is involved in lipid me-
tabolism, gluconeogenesis, and cell survival. PPAR is of 
interest owing to its protective effect on IRI. Although the 
effects of PPAR in cardiac, cerebral, hepatic, and renal IRI 
have already been studied, the precise role of PPAR and its 
potential as a therapeutic agent remain relatively under-
researched [23-25]. However, various experimental studies 
have shown PPAR to be involved in renal IRI. PPAR ago-
nists have been shown to reduce IRI [26-28]. Although there 
is no direct evidence of the role of PPAR-δ in renal IRI, a 
study has demonstrated the agonist activity of PPAR-γ and 
PPAR-δ [29]. In this present study, we described the potential 
role of PPAR in the mechanism of CORM-3. However, fur-
ther research is warranted to validate our findings.
A limitation of this study is that we could not perform 
experiments using larger animals that closely resemble isch-
emic injury in humans. In order to use CORM-3 as a treat-
ment for IRI, safety assessment in humans will be necessary. 
Additionally, a negative control group using an inactive 
form of CORM-3 was not investigated. Nevertheless, our in 
vivo experiments using rats demonstrated that CORM-3 has 
potential for use as a pretreatment agent in laparoscopic 
or robotic partial nephrectomy to cause warm IRI. To our 
knowledge, this is the first study providing in vivo evidence 
supporting the use of CORM-3 in humans.
CONCLUSIONS
In conclusion, CORM-3 inhibits the progression of acute 
renal injury due to IRI by reducing inflammation and renal 
cell death. Moreover, CORM-3 reduces the inflammatory 
response of renal cells and suppresses apoptosis. The PPAR 
pathway suppresses responses associated with cell death 
and plays an important role in the mechanism of CORM-3. 
Through further human studies, we expect that pretreat-
ment with CORM-3 in partial nephrectomy and kidney 
transplantation will minimize renal IRI.
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Fig. 9. Identification of changes in gene expression related to the 
peroxisome proliferator-activated receptors (PPAR) signaling pathway. 
IRI, ischemia-reperfusion injury; CORM-3, carbon monoxide–releasing 
molecule-3; CYP4A1, cytochrome P450, family 4, subfamily a; LXR, liver 
X receptor; RXR, retinoid X receptor; PEPCK, phosphoenolpyruvate 
carboxykinase; Gyk, glycerol kinase; MCAD, medium chain acyl dehy-
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